What does PALISEUL PHARMA do?

PALISEUL PHARMA is a pharmacy in Paliseul. Private Limited, started on 7 July 2005, 1 establishment.

What is the address of PALISEUL PHARMA?

The registered office of PALISEUL PHARMA is located at Grand-Place 16, 6850 Paliseul.

Is PALISEUL PHARMA still active?

Yes. According to the CBE (30 October 2026) PALISEUL PHARMA is active, legal situation “Normale toestand”, started on 7 July 2005.

Is PALISEUL PHARMA registered on Peppol?

Yes, PALISEUL PHARMA is registered on the Peppol network with ID 0208:0874952569.

What is the enterprise number of PALISEUL PHARMA?

The enterprise number of PALISEUL PHARMA is BE0874952569.

When was PALISEUL PHARMA founded?

PALISEUL PHARMA was founded on 7 July 2005.

Who are the directors of PALISEUL PHARMA?

According to the 2025 annual accounts, the directors of PALISEUL PHARMA are: PO² SRL.

Is PALISEUL PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 July 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PALISEUL PHARMA make in 2025?

PALISEUL PHARMA posted a profit after taxes of € 183,716 in financial year 2025.

What is the revenue of PALISEUL PHARMA?

As a small company, PALISEUL PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 691,915.

How much does an employee at PALISEUL PHARMA earn?

The average wage cost per full-time employee at PALISEUL PHARMA was € 72,100 in 2025: staff costs of € 259,507 for 3.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PALISEUL PHARMA have?

According to the 2025 annual accounts, PALISEUL PHARMA has 3.6 full-time equivalents (FTE).

PALISEUL PHARMA (Private Limited) - Paliseul

Dossier PALISEUL PHARMA, printed on 30 October 2026 from databakkes.be/en/0874952569/paliseul-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PALISEUL PHARMA from Paliseul, company number BE0874952569, closed financial year 2025 with a result of € 183,716 after tax. For that financial year PALISEUL PHARMA recorded a gross margin of € 691,915 and equity of € 906,153. Compared with financial year 2024, the result moved from € 180,201 to € 183,716. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.

What it is worth Growing

€ 906,153

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 183,716

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 583,012

▲ 30% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 110,000 paid out

60 % of the profit went to the shareholders, mostly to PO² (99 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

3.6

▲ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 259,507

▲ 23% vs 2024

€ 72,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 133,146

▼ 11% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.3 million

▼ 7% vs 2024

€ 107,612 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 277,293

▼ 37% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 51,499

▼ 2% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 412,982 Gross margin 2022: € 412,982 First fiscal year in the series	€ 424,071 Gross margin 2023: € 424,071 ▲ 3% vs 2022 (€ 412,982) Favourable step	€ 472,789 Gross margin 2024: € 472,789 ▲ 11% vs 2023 (€ 424,071) Favourable step	€ 691,915 Gross margin 2025: € 691,915 ▲ 46% vs 2024 (€ 472,789) Favourable step	▲ 46%
Profit after taxes	€ 169,460 Profit after taxes 2022: € 169,460 First fiscal year in the series	€ 190,005 Profit after taxes 2023: € 190,005 ▲ 12% vs 2022 (€ 169,460) Favourable step	€ 180,201 Profit after taxes 2024: € 180,201 ▼ 5% vs 2023 (€ 190,005) Unfavourable step	€ 183,716 Profit after taxes 2025: € 183,716 ▲ 2% vs 2024 (€ 180,201) Favourable step	▲ 2%
Equity	€ 562,231 Equity 2022: € 562,231 First fiscal year in the series	€ 692,236 Equity 2023: € 692,236 ▲ 23% vs 2022 (€ 562,231) Favourable step	€ 832,437 Equity 2024: € 832,437 ▲ 20% vs 2023 (€ 692,236) Favourable step	€ 906,153 Equity 2025: € 906,153 ▲ 9% vs 2024 (€ 832,437) Favourable step	▲ 9%
Total debts	€ 540,171 Total debts 2022: € 540,171 First fiscal year in the series	€ 485,691 Total debts 2023: € 485,691 ▼ 10% vs 2022 (€ 540,171) Favourable step	€ 1,927,430 Total debts 2024: € 1,927,430 ▲ 297% vs 2023 (€ 485,691) Unfavourable step	€ 1,725,330 Total debts 2025: € 1,725,330 ▼ 10% vs 2024 (€ 1,927,430) Favourable step	▼ 10%
Cash	€ 230,919 Cash 2022: € 230,919 First fiscal year in the series	€ 271,987 Cash 2023: € 271,987 ▲ 18% vs 2022 (€ 230,919) Favourable step	€ 448,164 Cash 2024: € 448,164 ▲ 65% vs 2023 (€ 271,987) Favourable step	€ 583,012 Cash 2025: € 583,012 ▲ 30% vs 2024 (€ 448,164) Favourable step	▲ 30%
Land & buildings	€ 210,616 Land & buildings 2022: € 210,616 First fiscal year in the series	€ 199,960 Land & buildings 2023: € 199,960 ▼ 5% vs 2022 (€ 210,616) Unchanged	€ 189,304 Land & buildings 2024: € 189,304 ▼ 5% vs 2023 (€ 199,960) Unchanged	€ 182,235 Land & buildings 2025: € 182,235 ▼ 4% vs 2024 (€ 189,304) Unchanged	▼ 4%
Retained profit	€ 556,031 Retained profit 2022: € 556,031 First fiscal year in the series	€ 686,036 Retained profit 2023: € 686,036 ▲ 23% vs 2022 (€ 556,031) Favourable step	€ 826,237 Retained profit 2024: € 826,237 ▲ 20% vs 2023 (€ 686,036) Favourable step	€ 899,953 Retained profit 2025: € 899,953 ▲ 9% vs 2024 (€ 826,237) Favourable step	▲ 9%
Dividend	€ 65,000 Dividend 2022: € 65,000 First fiscal year in the series	€ 60,000 Dividend 2023: € 60,000 ▼ 8% vs 2022 (€ 65,000) Unchanged	€ 40,000 Dividend 2024: € 40,000 ▼ 33% vs 2023 (€ 60,000) Unchanged	€ 110,000 Dividend 2025: € 110,000 ▲ 175% vs 2024 (€ 40,000) Unchanged	▲ 175%
Bank debt	€ 195,632 Bank debt 2022: € 195,632 First fiscal year in the series	€ 181,100 Bank debt 2023: € 181,100 ▼ 7% vs 2022 (€ 195,632) Favourable step	€ 1,389,192 Bank debt 2024: € 1,389,192 ▲ € 1.2 million vs 2023 (€ 181,100) Unfavourable step	€ 1,286,156 Bank debt 2025: € 1,286,156 ▼ 7% vs 2024 (€ 1,389,192) Favourable step	▼ 7%
Balance sheet total	€ 1,102,402 Balance sheet total 2022: € 1,102,402 First fiscal year in the series	€ 1,177,927 Balance sheet total 2023: € 1,177,927 ▲ 7% vs 2022 (€ 1,102,402) Unchanged	€ 2,759,867 Balance sheet total 2024: € 2,759,867 ▲ 134% vs 2023 (€ 1,177,927) Unchanged	€ 2,631,484 Balance sheet total 2025: € 2,631,484 ▼ 5% vs 2024 (€ 2,759,867) Unchanged	▼ 5%
Employees (FTE)	3.5 Employees (FTE) 2022: 3.5 First fiscal year in the series	3.3 Employees (FTE) 2023: 3.3 ▼ 0.2 vs 2022 (3.5) Unchanged	3.4 Employees (FTE) 2024: 3.4 ▲ 0.1 vs 2023 (3.3) Unchanged	3.6 Employees (FTE) 2025: 3.6 ▲ 0.2 vs 2024 (3.4) Unchanged	▲ 0.2

Key figures of PALISEUL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PALISEUL PHARMA?

What happened at PALISEUL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 15, 2026 New annual accounts for financial year 2025: profit of € 183,716 (▲ 2% vs 2024). Source: NBB ↗
2015 PO² SRL became a director. NBB
Jul 20, 2005 New establishment in Paliseul. KBO
Jul 7, 2005 Start of the company according to the CBE. KBO

In short

From € 169,460 profit in 2022 to € 183,716 profit in 2025.

Paid € 154,049 in corporate taxes since 2022.

Best year ever: 2023, with € 190,005 profit.

On average € 192,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PO² 99%

The stake of PO² comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PALISEUL PHARMA

Behind PALISEUL PHARMA is PO² SRL. The shares are held by PO² (99%).

Directors

According to the 2025 annual accounts

PO² SRL

Director · represented by Philippe ROBYN

Also active at: PHARMA BIOMED

since 2015

Shareholders

PO²

99%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Grand-Place 16

6850 Paliseul

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0874.952.569

VAT number

BE 0874.952.569

Registered office

Grand-Place 16, 6850 Paliseul

Names & denominations

PALISEUL PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 July 2005

Peppol

Active · Active since 24 Nov 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PALISEUL PHARMA

Financials

What happened to PALISEUL PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions